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Abstract: Chronic overnutrition and consequential visceral obesity is associated with a cluster 
of risk factors for cardiovascular disease and type 2 diabetes mellitus. Moreover, individuals who 
have a triad of hypertension, dysglycemia, and elevated triglycerides along with reduced high-
density lipoprotein cholesterol have a greater residual cardiovascular risk even after factoring for 
the traditional risk factors such as age, smoking, diabetes, and elevated low-density lipoprotein 
cholesterol. In our previous study we demonstrated that TRC150094, when administered to 
rats receiving a high-fat diet, stimulated mitochondrial fatty acid oxidation (FAO) and reduced 
visceral adiposity, opening an interesting perspective for a possible clinical application. In the 
present study, oral administration of TRC150094 to obese Zucker spontaneously hypertensive 
fatty rats (obese ZSF1) improved glucose tolerance and glycemic profile as well as attenu-
ated a rise in blood pressure. Obese ZSF1 rats treated with TRC150094 also showed reduced 
hepatic steatosis, reduced progression of nephropathy, and improved skeletal muscle function. 
At the cellular level, TRC150094 induced a significant increase in mitochondrial respiration as 
well as an increased FAO in liver and skeletal muscle, ultimately resulting in reduced hepatic 
as well as total body fat accumulation, as evaluated by magnetic resonance spectroscopy and 
magnetic resonance imaging, respectively. If reproduced in humans, these results could confirm 
that TRC150094 may represent an attractive therapeutic agent to counteract multiple residual 
cardiovascular risk components.
Keywords: CV risk factors, energy expenditure, fatty acid oxidation, obesity, TRC150094, 
type 2 diabetes
Introduction
Excess caloric intake and/or a sedentary lifestyle are the obvious culprits that lead to 
obesity and insulin resistance, which eventually progresses to type 2 diabetes mellitus.1 
Not all obese individuals carry an increased cardiovascular (CV) risk beyond the tra-
ditional risk factors; however, patients in whom a cluster of several nontraditional risk 
factors associated with CV disease occur together, carry a relatively higher absolute 
risk of CV events.2 This cluster includes ectopic lipid deposition exemplified by non-
alcoholic fatty liver disease,3–5 carbohydrate intolerance,6 atherogenic dyslipidemia,7 
and hypertension.8 Several studies have reported that individuals who have a triad of 
hypertension, dysglycemia, and elevated triglycerides along with reduced high-density 
lipoprotein (HDL) cholesterol (atherogenic dyslipidemia) have a greater residual CV 
risk even after factoring for the traditional risk factors such as age, smoking, diabetes, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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and elevated low-density lipoprotein (LDL) cholesterol.9–11 
Regular physical activity and reduction of caloric intake 
represent the ideal strategy to counteract this syndrome,12 
which is rarely achieved in real life. Therefore, much effort 
is being devoted to develop agents useful in counteracting the 
aforementioned metabolic abnormalities. Current standards 
of care for CV disease prevention emphasize the importance 
of multifactorial intervention to achieve recommended targets 
for LDL cholesterol, blood pressure, and glycemic control.13,14 
Although several treatment options exist for individual com-
ponents of this cluster, an optimal approach aimed at correct-
ing the metabolic derangement is of paramount importance 
in order to target residual CV risks.15
TRC150094 is a novel synthetic compound that 
displays the capacity to stimulate energy expenditure. 
In our recently published study, we have demonstrated that 
TRC150094 increases whole body energy expenditure, 
increases mitochondrial fatty acid oxidation (FAO), and 
reduces abdominal adiposity in rats fed a high-fat diet.16 
These findings provoked the evaluation of the potential of 
TRC150094 for the treatment of a cluster of multiple CV risk 
factors associated with visceral obesity and associated meta-
bolic derangement. Hence, the present study was designed to 
evaluate the effects of TRC150094 in an animal model that 
spontaneously displays a phenotype akin to patients with the 
aforementioned cluster of nontraditional CV risk factors.
In the present study, we have employed obese ZSF1 
rats, an animal model that spontaneously develops obesity 
and dysglycemia as well as an associated clinically relevant 
constellation of comorbidities. Indeed, adult obese ZSF1 
rats exhibit many of the features common to human meta-
bolic syndrome, including obesity, hyperglycemia, insulin 
  resistance, hypertension, and severe dyslipidemia.17
Material and methods
Animals, grouping, and treatment
Male obese ZSF1 rats (Charles River Laboratories, 
  Wilmington, MA, USA) 12 weeks in age (n = 30) were used 
for the study. Principles of laboratory animal care,18 as well 
as Committee for the Purpose of Control and Supervision of 
Experiments on Animals guidelines for animal care19 were 
followed. Rats were housed in individually ventilated cage 
systems, maintained on a 12-hour light–dark cycle, and had 
access to Purina 5008 rat chow and water ad libitum. The indi-
vidually ventilated cages were maintained under a controlled 
environment of temperature 22 ± 3°C, relative humidity 
30%–70%, and air exchange rate 40–50 air changes per hour. 
Some of the rats (n = 10) were implanted with radiotelemetry 
implants (TL11M2C50PXT, Data   Sciences, St Paul, MN, 
USA) at the age of 6–8 weeks. At the age of 3 months, all 
obese ZSF1 rats were divided into three groups: control, 
6 mg/kg (receiving TRC150094 6 mg/kg/d orally twice daily), 
and 12 mg/kg (receiving TRC150094, 12 mg/kg/d orally 
twice daily). The grouping was done such that the control 
and 12 mg/kg groups included five rats per group that were 
implanted with radiotelemetry implants.
Blood pressure recording 
by radiotelemetry
The influence of long-term treatment on blood pressure, one 
of the very relevant triad components associated with CV risk 
in metabolic syndrome, was measured using a radiotelemetry 
system (Dataquest A.R.T. 3.01, Data Sciences International, 
St Paul, MN, USA). Scheduled rat cages were placed on 
top of a receiver (RPC1, Data Sciences) for measurement 
of blood pressure, which was recorded from rats implanted 
with TL11M2C50PXT transmitters. Data were collected 
with a computer-driven data acquisition system (Dataquest 
A.R.T. 3.01, Data Sciences); the acquisition software was 
appropriately configured to record parameters for 30 seconds 
every 10 minutes, continuously for 24 hours. The systolic 
blood pressure (SBP) and diastolic blood pressure (DBP) 
data acquired were analyzed and represented as light time 
(mean of daytime data) and dark time (mean of nighttime 
data) blood pressure.
Body fat and liver fat measurement
A magnetic resonance imaging (MRI) technique was used to 
assess the influence of TRC150094 on whole body fat and 
liver fat accumulation. For MRI and magnetic resonance 
spectroscopy (MRS) acquisition, anesthesia was induced 
by inhalation of a mixture of oxygen and 5%   isoflurane and 
maintained with a mixture of oxygen containing 2%–2.5% 
isoflurane. Anesthetized obese ZSF1 rats were placed in a 
supine position in a quadrature transmit/receive head coil 
(length 28 cm and height 26 cm). All MRI/MRS experiments 
were carried out using a Philips model, ACHIEVA, equipped 
with a 3 Tesla horizontal magnet with a 60 cm bore. View 
forum R6-1V1L2SP 2007 was used to analyze data.
For measurement of total body fat (n = 6 rats per group), 
radiofrequency pulses were transmitted, and the nuclear 
magnetic resonance signal was acquired with quadrature 
transmit/receive head coil. Contiguous transversal slices 
were obtained along the rat length using a T1 weighted-spin 
echo and fat suppress technique with 128 phase-encoding 
steps. The imaging sequence was optimized for short echo Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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time (echo time 15 milliseconds) and short repetition time 
(repetition time 673 milliseconds) to allow for signal suppres-
sion from tissues other than fat. Usually, 3-mm-thick coronal 
slices were obtained of a total of 20 images to cover the whole 
body with FOV 259 mm and NEX-2. Two-dimensional image 
series were then imported to view forum R6-1V1L2SP 2007 
Philips software for estimation of fat volumes.
A stimulated echo acquisition method (SV-STEAM) was 
used in conjunction with CHESS sequence to suppress the 
water signals for MRS acquisition. The acquisition param-
eters were: 2000/21 (repetition time milliseconds/echo time 
milliseconds), 2000 Hz sweep width, 1024 data points, and 
128 images. Total acquisition time with respiratory trigger 
was 25 minutes.
For measurement of hepatic fat by MRS in obese ZSF1 
rat SV-STEAM spectra were acquired in the supine position. 
A localization voxel of 5 mm3 was placed in the right hepatic 
lobe of the liver, adjacent to the portal vein near the edge 
of the liver, with care taken to avoid the large intrahepatic 
vessels. To diminish tissue contamination from the adjacent 
structures and to maintain proper localization, all voxels were 
positioned by individuals experienced in abdominal radiol-
ogy. A respiratory trigger was applied longitudinally over the 
body surface to avoid artifacts due to irregular respiration.
Oral glucose tolerance and fasting 
plasma biochemical parameters
An oral glucose tolerance test (OGTT) was performed at 
week 6 and week 24. At time 0 minutes, blood collection was 
performed in 8-hour-fasted obese ZSF1 rats under light iso-
flurane anesthesia from the sublingual vein. Glucose was then 
administered orally at a dose of 2 g/kg with a dose volume of 
4 mL/kg. Blood was collected at 15, 30, 60, and 120 minutes 
after glucose load. Plasma was separated for estimation of 
glucose. Blood samples were collected from 8-hour-fasted 
obese ZSF1 rats for measurement of fasting plasma glucose, 
cholesterol, and triglycerides at weeks 0, 6, 16, and 24. 
Plasma fructosamine levels were measured from the blood 
samples collected at treatment week 24. For   measurement of 
random plasma glucose levels, blood samples were collected 
at 8.00 a.m. from nonfasted rats at weeks 0, 5, and 24.
effect on forelimb grip strength
The forelimb grip strength in rats was measured using a 
Grip Strength Meter (Columbus Instruments International, 
Columbus, OH, USA). Rats were held by the scruff of the 
neck with one hand, and at the base of the tail with the other. 
The forepaws were located within the pull bar connected to 
the force gauges and the rat slowly pulled away from the pull 
bar until it released the pull bar.
Measurement of mitochondrial 
respiratory parameters, FAO, 
and carnitine palmitoyl transferase 
activity assay
In our previous study, in Wistar rats fed a high-fat diet it was 
demonstrated that TRC150094 influences the mitochondrial 
substrate oxidation in skeletal muscle and liver.16 In our 
present study, we also monitored terminally the mitochon-
drial respiratory parameters, FAO, and carnitine palmitoyl 
transferase (CPT) activity assay to assess whether chronic 
administration of TRC150094 likewise influences the mito-
chondrial substrate oxidation capacity in obese ZSF1 rats that 
maintained on a relatively high carbohydrate diet.
isolation of mitochondria
At the end of treatment duration, rats were euthanized and 
  tissues such as liver and hind limb skeletal muscles were 
excised and minced in an ice-cold buffer consisting of 220 mM 
mannitol, 70 mM sucrose, 20 mM Tris-HCl, 1 mM ethylene-
diaminetetraacetic acid (EDTA), and 5 mM ethylene glycol 
tetraacetic acid (EGTA) (pH 7.4), and then homogenized in 
a Potter–Elvehjem homogenizer. Nuclei and cell debris were 
removed by centrifugation at 500 g for 10   minutes, with the 
resulting supernatant being centrifuged at 3000 g for liver 
and 8000 g for skeletal muscle.21 The mitochondrial pellet 
was washed twice and resuspended in a minimal volume 
of isolation medium and kept on ice until used. The protein 
concentration was determined by the Hartree method, using 
bovine serum albumin (BSA) as standard.
Mitochondrial respiration
Succinate-induced state 4 respiration (uncoupled respira-
tion in which there is no phosphorylation of adenosine 
diphosphate [ADP] to adenosine triphosphate) and state 3 
respiration (coupled respiration in which phosphorylation 
of ADP is at the maximal rate) of isolated mitochondria 
(0.2 mg) were determined polarographically at 37°C using 
a Clark-type electrode (Oxytherm, Hansatech Instruments 
Limited, Norfolk, UK) in 1 mL of respiratory medium 
consisting of 80 mM KCl, 50 mM 4-(2-hydroxyethyl)-1-
  piperazineethanesulfonic acid (HEPES), 1 mM EGTA, 1 mM 
EDTA, 5 mM KH2PO4, 2 mM MgCl2, 5 mM succinate, 4 µM 
rotenone, and 1% BSA (pH 7.0). Rotenone was added to 
inhibit complex I of the electron transport chain.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Measurement of FAO rate
The rate of mitochondrial (0.5 mg) FAO was assessed 
polarographically using a Clark-type electrode at 30°C 
in a final volume of 1 mL of 80 mM KCl, 50 mM HEPES 
(pH 7.0), 1 mM EGTA, 5 mM K2HPO4, 1% BSA (w/v), 
and 2.5 mM malate in the presence of ADP (200 µM). The 
reaction was started by the addition of palmitoyl coenzyme 
A (CoA) in the presence of 2 mM carnitine, the oxidation 
of which requires its import into the mitochondrion, an 
influx mediated by CPT or with palmitoyl–carnitine CPT-
independent FAO.
cPT activity assay
To measure CPT activity, frozen (−70°C) mitochondria were 
used. Total CPT (CPT1 plus CPT2) activity was measured 
spectrophotometrically (412 nm) by following the kinetics 
of 2 mM carnitine-dependent CoASH production in the 
presence of 300 µM 5,5′-dithio-bis(2-nitrobenzoic acid) 
using 50 µM palmitoyl-CoA as a substrate. The reaction of 
palmitoyl CoA in the presence of beta dystrobrevin (DTNB) 
indicates the involvement of other mitochondrial enzymes.
citrate synthase activity measurement
Citrate synthase activity was measured from freshly 
  isolated mitochondria from skeletal muscle by an assay kit 
from Sigma (CS0720). Assay was performed using acetyl 
CoA, oxaloacetate, and DTNB. Production of CoASH was 
  measured spectrophotometrically at 412 nm.
histopathological evaluation
Sections of liver and kidney tissues were fixed in 10% neutral 
buffer formalin for histopathology   evaluation. After 3–4 days 
of fixation, 2–3 mm thick tissues were trimmed and 
  processed for paraffin sectioning.   Four-micron-thick 2–3-
serial sections were taken from Leica microtome. Transverse 
sections of kidney were stained with routine hematoxylin and 
eosin, Periodic acid Schiff (PAS), and Masson’s trichrome 
stain.22 The   PAS-stained kidney sections were evaluated for 
nephropathic, tubulopathic, and glomerulosclerotic changes 
on a scale of grade 0 to 4.17,20,23
Liver was microscopically examined in hematoxylin 
and eosin and PAS-stained sections22 on the grade scale of 
0 to 4. In addition to this, a formalin-fixed cryosection of 
liver was also stained with Churukian Oil Red method20 
for   confirmation of hepatosteatosis. All histopathological 
  evaluation was performed on coded slides.
All studies consisted of n $ 4 rats per group.   Statistics 
were conducted using Student’s t-test (*P , 0.05, 
**P , 0.01, ***P , 0.1 vs control) and analysis of variance 
(ANOVA) followed by Dunnett’s test (#P , 0.05, ##P , 0.1 
vs control). Statistical significance was defined as one-sided 
P values.
Results
effect on visceral fat accumulation
Whole body fat was measured by MRI, and liver fat was 
quantified by MRS. TRC150094 treatment significantly 
attenuated liver fat accumulation, which represents a reduc-
tion of visceral fat accumulation (Table 1).
The control group showed increased body fat accumu-
lation with age progression, whereas TRC150094-treated 
male obese ZSF1 rats showed a significant lower fat 
accumulation (Table 1), which was evident from week 4 
of treatment.
effect on steatohepatitis
Male obese ZSF1 rats developed steatohepatitis as indicated 
by a progressive rise in liver fat accumulation and plasma 
bilirubin with age. TRC150094 treatment resulted in lower 
levels of plasma bilirubin (at 24 weeks: 2-fold increase in the 
TRC150094 12 mg/kg-treated group vs 8-fold increase in the 
control group with respect to pretreatment levels) along with 
Table 1 effect of Trc150094 on body fat and liver fat in male obese ZSF1 rats
Parameter Treatment  
week
Control TRC150094  
6 mg/kg
TRC150094  
12 mg/kg
Body fat (mm3) 0
4
16
24
220 ± 19.6
330 ± 30.3
290 ± 29.6
287 ± 11.2
237 ± 25.6
271 ± 24.1**
257 ± 12.2
244 ± 13.1*, #
229 ± 14.5
270 ± 17.8**, #
253 ± 30.1
268 ± 17.2
Liver fat (peak area, ppm) 0
4
16
24
199 ± 11.8
259 ± 22.4
304 ± 44.6
315 ± 35.1
173 ± 15.0
188 ± 27.9**
174 ± 15.1*, #
176 ± 35.2
190 ± 27.2
186 ± 28.8**, #
160 ± 46.3*, #
174 ± 59.6
Notes: Values are mean ± SeM. *P , 0.05; **P , 0.1 vs control group (Student’s t-test ); #P , 0.1 vs control (ANOVA followed by Dunnett’s post hoc test), n ≥ 5.
Abbreviations: AnOVA, analysis of variance; ppm, parts per million; SeM, standard error of mean.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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a concurrent reduction in liver fat accumulation as observed 
in MRS and terminal histopathological evaluation (Figure 1), 
indicating attenuation of steatohepatitis.
Effect on glycemic profile
Visceral fat accumulation is associated with insulin 
resistance and diabetes. Hence, effects of TRC150094 
on various   glycemic parameters were evaluated in obese 
ZSF1 rats. At the age of 7 weeks, male obese ZSF1 rats 
were hyperglycemic and hyperinsulinemic. TRC150094 
treatment resulted in a significant reduction in fasting 
hyperglycemia, reduced AUCglucose (area under the glu-
cose response curve) during OGTT, and improved plasma 
fructosamine levels (Table 2). This demonstrates that 
TRC150094 treatment enhanced glucose utilization and 
improved glycemic profile.
effect on blood pressure
In obese ZSF1 rats, blood pressure rises as age progresses. 
TRC150094 treatment attenuated a rise in blood pressure 
with progression of age. In the TRC150094-treated group, 
progression of both SBP and DBP were significantly 
lower as compared with the control group (P , 0.01, 
  repeated-measures ANOVA, Figure 2A and 2B).
effect on nephropathy
Male obese ZSF1 rats exhibited symptoms of progressive 
diabetic nephropathy from the age of 12 weeks. Histo-
pathological observations of the kidney tissue indicated 
that TRC150094 12 mg/kg treatment in obese ZSF1 rats 
reduced progression of nephropathy and glomerulosclerosis 
(Figure 3A and 3B).
At 6 and 16 weeks of treatment, TRC150094 12 mg/kg 
reduced the extent of glycosuria by 285 and 1832 mg/day 
and proteinuria by 12 and 120 mg/day, respectively. Urinary 
microalbumin was also less by 285 and 1832 mg/day in the 
TRC150094 12 mg/kg group than in the control group at 
6 and 16 weeks of treatment, respectively. These findings 
further substantiated the aforementioned histopathological 
observations of slow progression of nephropathy in the 
TRC150094-treated group.
effect on skeletal muscle function
About a 117% increase in citrate synthase activity, a marker of 
aerobic capacity, and mitochondrial density in skeletal muscle, 
was observed in the gastrocnemius muscle of male obese 
ZSF1 rats in the TRC150094-treated group 2.31 ± 0.57 µmol/
mg/minute vs 1.1 ± 0.3 µmol/mg/minute in the control 
group. Also, muscle grip strength, a functional parameter 
of skeletal muscle, was found to be better preserved in the 
AB C
DE F
Figure 1 A) hematoxylin and eosin D) Oil red O liver sections of a control-
treated obese ZSF1 rat showing a high number of hepatocytes with fat droplets;   
B) hematoxylin and eosin E) Oil red O liver sections of a Trc150094 (6 mg/kg 
body weight)-treated obese ZSF1 rat showing fewer hepatocytes with fat droplets; 
C) hematoxylin and eosin F) Oil red O liver sections of a Trc150094 (12 mg/kg 
body weight)-treated obese ZSF1 rat showing the least number of hepatocytes with 
fat droplets (100× magnification).
Table 2 effect of Trc150094 on glycemic parameters in male obese ZSF1 rats
Parameter Treatment 
week
Control TRC150094 
6 mg/kg
TRC150094 
12 mg/kg
Fasting plasma  
glucose (mg/dL)
0
6
16
24
286.3 ± 16.7
328.2 ± 20.4
294.6 ± 15.1
232.6 ± 15.0
292.7 ± 17.4
299.3 ± 24.3*
243.6 ± 14.5*, #
193.8 ± 15.1*, ##
280.6 ± 15.8
250.4 ± 21.9*, #
269.2 ± 10.9
206.5 ± 9.2***
random plasma  
glucose (mg/dL)
0
5
24
490.8 ± 13.0
494.2 ± 16.0
364.9 ± 30.7
500.7 ± 14.8
454.9 ± 20.0
303.2 ± 27.8***
488.9 ± 11.1
433.4 ± 23.8
317.9 ± 29.5*, ##
AUcglucose during  
OgTT (mg*h/dL)
0
6
24
977.8 ± 31.0
997.6 ± 32.5
726.1 ± 38.7
952 ± 29.1
886.5 ± 36.8*, #
568 ± 24.5**, #
930.0 ± 29.9
813.9 ± 68.9*, #
554.9 ± 50.6*, #
Fructosamine (µmol/L) 24 345.5 ± 57.0 354.1 ± 41.1 252.3 ± 23.2***, ##
Notes: Values are mean ± SeM. *P , 0.05; **P , 0.01; ***P , 0.1 vs control group (Student’s t-test ); #P , 0.05; ##P , 0.1 vs control (AnOVA followed by Dunnett’s post 
hoc test), n = 8–10.
Abbreviations: AnOVA, analysis of variance; AUcglucose, area under the glucose response curve; OgTT, oral glucose tolerance test; SeM, standard error of mean.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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TRC150094-treated group 341.2 ± 15.9 vs 267.9 ± 13.6 
(pressure, gm) in the control group.
effect on mitochondrial respiration 
capacity to import and oxidize fatty  
acids in metabolically active tissues
Respiratory parameters were measured in mitochon-
dria isolated from the liver and skeletal muscle for 
both control- and TRC150094-treated obese ZSF1 rats. 
Significant enhancement in mitochondrial respiration 
(both state 3 and state 4) was observed in tissues of 
rats treated with TRC150094 as compared with control   
(Table 3).
Next, the activity of the CPT system (the rate-limiting 
step for mitochondrial fatty acid uptake) and the ability of 
mitochondria to import and oxidize fatty acids and mito-
chondrial FAO rate were measured in the liver and skeletal 
muscle of both control and TRC150094-treated obese ZSF1 
rats (Table 3).
In liver and skeletal muscle, TRC150094 treatment 
resulted in enhancement of both CPT dependence (28% 
each) and CPT independence (37% and 46%, respectively) 
FAO (Table 3).
Discussion
Recently, we have shown that TRC150094 has significant 
metabolic effects but minimal activity toward the thyroid 
receptors and is therefore devoid of adverse effects on the 
heart associated with thyroid receptor hyperactivation. The 
same study also demonstrates that TRC150094 increases 
mitochondrial FAO and respiratory chain activity and thereby 
increases resting metabolic rate in Wistar rats fed a high-
fat diet.16 In the present study, we employed male obese ZSF1 
rats on a diet that was not unduly rich in fat (PURINA 5008, 
2
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Figure 2 A) effect of Trc150094 (12 mg/kg body weight) on SBP in obese ZSF1 rats; B) effect of Trc150094 (12 mg/kg body weight) on DBP in obese ZSF1 rats. The solid 
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7% fat) that exhibited more severe obesity, type 2 diabetes, 
and a cluster of other metabolic abnormalities. Male obese 
ZSF1 rats exhibited fairly well characterized features of meta-
bolic syndrome such as severe obesity, hyperlipidemia (hyper-
tryglyceridemia and hypercholesterolemia), hyperglycemia, 
hyperinsulinemia, and hypertension. Obese ZSF1 rats died 
(at the age of ∼12 months) with symptoms of end-stage renal 
failure accompanied by marked cardiac hypertrophy.20
TRC150094 prevented the accumulation of visceral fat 
in obese ZSF1 rats, at least in part by increasing energy 
expenditure, as demonstrated in our previous study in rats fed 
a high-fat diet. The increase in slow oxidative-type skeletal 
muscle fiber enhanced mitochondrial respiratory chain activ-
ity and FAO in TRC150094-treated obese ZSF1 rats, which 
substantiates that a similar mechanism is responsible for an 
increase in energy expenditure. In the present study, we found 
that long-term treatment with TRC150094 not only attenuated 
visceral fat accumulation in obese ZSF1 rats but also posi-
tively influenced various CV risk components associated with 
obese dysglycemic patients. For instance, long-term treatment 
of obese ZSF1 rats with TRC150094 improved glucose toler-
ance and glycemic profile, attenuated a rise in blood pressure, 
and improved functional capacity of skeletal muscle. The 
obese ZSF1 rats were hyperglycemic and as age progressed 
they progressively developed nephropathy. The improvement 
in glycemic control in TRC150094-treated rats resulted in 
reduced glycosuria and protienurea in obese ZSF1 rats in an 
early treatment period (6–16 weeks of treatment period), and 
thus slowed down the progression of nephropathy.
In the present study, the effect on blood pressure appeared 
noticeable after 4–6 weeks of treatment. As there is a relation-
ship between insulin resistance and deterioration of endothelial 
function,24 better blood pressure control in TRC150094-treated 
rats is likely mediated through improved insulin   sensitivity. 
This finding has immense clinical   relevance. A Global Car-
diometabolic Risk Profile in Patients with Hypertension 
Disease (GOOD) survey reported that blood pressure control 
was significantly worse in hypertensive patients with diabe-
tes mellitus and/or metabolic syndrome. Moreover, 95% of 
patients with both metabolic syndrome and type 2 diabetes 
had poorly controlled blood pressure.25
One additional observation from this study was that 
obese ZSF1 rats exhibited distinct differences in param-
eters such as body weight gain, fat accumulation, and lipid 
profile after TRC150094 treatment than a control group in 
Table 3 effect of Trc150094 12 mg/kg/d treatment on liver and skeletal muscle mitochondrial parameters in male obese ZSF1 rats
Parameter Liver Skeletal muscle
Control Treated Control Treated
Respiratory parameters
State 4 respiration
(nmol/mg/min)
54.1 ± 8.2 68.1 ± 6.3 67.8 ± 12.7 104.7 ± 11.35*
State 3 respiration 
(nmol/mg/min)
193.5 ± 17.5 260.4 ± 22.0* 198.4 ± 28.8 301.86 ± 20.94*
Fatty acid oxidation (FAO)
FAO/palmitoyl coA 
(nmol/mg/min)
29.3 ± 2.1 37.3 ± 3.9* 28.9 ± 5.2 36.96 ± 7.66
FAO/palmitoyl carnitine 39.3 ± 5.3 53.9 ± 3.1* 42.7 ± 2.2 62.4 ± 6.3**
cPT activity 
(nmolcoA/mg/min)
23.98 ± 3.0 28.13 ± 1.5 17.6 ± 2.7 21.23 ± 3.8
Notes: Values are mean ± SeM (standard error of mean). *P , 0.05; **P , 0.01 vs control group (n ≥ 5).
Abbreviations: coA, coenzyme A; cPT, carnitine palmitoyl transferase; SeM, standard error of mean.
Vehicle A
B
6 mg/kg 12 mg/kg
Vehicle 6 mg/kg 12 mg/kg
Figure  3  A)  hematoxylin  and  eosin-stained  representative  kidney  sections. 
control-treated obese ZSF1 rat with severe nephropathy; Trc150094 6 mg/kg body 
weight and 12 mg/kg body weight-treated rat, respectively, with reduced grade of 
nephropathy. (red arrows showing dilated tubules and blue arrows showing hyaline 
cast). (100× magnification) B) PAS-stained kidney sections. glomerulus showing 
moderate  glomerulosclerosis  in  control-treated  and  Trc150094  6  mg/kg  body 
weight-treated rat, illustrated by global expansion of mesangial matrix (pink stained, 
yellow arrow), thickened basement membrane (black arrow) with infiltration of 
foam cells (green arrow). glomerulus of 12 mg/kg showed milder glomerulosclerosis 
characterized by expansion of mesangial matrix (pink stained, yellow arrow) and 
normal capillaries and glomeruli (blue arrow) portion indicating improvement in 
nephropathy. (×400) For details refer to supplementary data.
Abbreviation: PAS, periodic acid Schiff.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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an early treatment period ie, 6–16 weeks. However, after 
16 weeks of treatment, the differences between these two 
groups diminished (data in Supplemental Information Tables 
A and B), though the mitochondrial substrate oxidation 
capacity (respiratory rate and FAO) remained high for the 
TRC150094 treatment group. This might be due to a reduc-
tion in weight gain in the control group because of a higher 
severity of progression of nephropathy and reduced food 
intake in obese ZSF1 rats.
The findings of the present study have significance in 
view of addressing the multiple CV risk factors associated 
with diabetes and obesity. About 85% of patients with type 
2 diabetes are abdominally obese and characterized by the 
atherothrombotic inflammatory profile as well as a cluster 
of CV risks such as high LDL cholesterol, hypertension, and 
low HDL cholesterol.13 Due to the constellation of abnormal-
ity at multiple biochemical, metabolic, and physiological 
components, the progression of disease involves progressive 
functional abnormality of multiple vital organs. As a con-
sequence, to aim at the optimal management of CV disease 
risk in type 2 diabetes, one must pay attention not only to the 
patient’s glycemic control but also to the accompanying mul-
tiple risk factors. Despite current standards of care for indi-
vidual risk factors such as LDL cholesterol, blood pressure, 
or glycemia, these interventions are insufficient to prevent 
the development or progression of microvascular disease in a 
significant proportion of obese type 2 diabetic patients. This 
has raised an urgent need for a renewed focus on developing 
agents that are capable of reducing the residual risk of CV 
events and microvascular complications in such patients.15 
The findings of the present study showed that TRC150094 
not only improved the individual component of multiple CV 
risks in the obese ZSF1 rats but also improved the associated 
complications, such as nephropathy and steatohepatitis.
Moreover, TRC150094 treatment also improved func-
tional capacity of skeletal muscle. Even though physical 
activity, including appropriate endurance and resistance 
training, is a major therapeutic modality for type 2 diabetes, 
it has been observed that the functional exercise capacity 
of those with type 2 diabetes is frequently lower than age-
matched nondiabetic counterparts.26 In view of this, the effect 
of TRC150094 on skeletal muscle fibre-type composition 
and metabolic capacity has immense significance for type 2 
diabetic subjects. Taken together, the findings of the present 
study reveal the potential of TRC150094 to attenuate the 
progression of metabolic derangement and microvascular 
complications associated with viscerally obese type 2 diabe-
tes at different vital organ levels. Hence, such an integrated 
approach regarding the progression or development of 
  multiple abnormalities has scope to minimize the residual 
CV risk in viscerally obese dysglycemic subjects.
Conclusion
This study demonstrates that TRC150094 attenuates the 
progression of hypertension, insulin resistance, dysglycemia, 
and atherogenic dyslipidemia, factors reported to signify 
significant CV risk amongst viscerally obese dysglycemic 
subjects. Moreover, at organ level, TRC150094 reduced 
steatohepatitis, reduced progression of nephropathy, and 
preserved cardiac contractile function.
If reproduced in humans, this pharmacological profile 
of TRC150094 may constitute a promising new class of 
molecules that may have a potential beneficial therapeutic 
approach for the treatment of nontraditional CV risk factors 
and may reduce residual risk in viscerally obese dysglyce-
mic patients. Moreover, the observed metabolic and func-
tional effects on skeletal muscle suggest that TRC150094 
as a therapy may help to facilitate adherence to prescribed 
exercise, which would remain the mainstay along with diet 
control in such patients.
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Body weight, food intake, 
and plasma lipid profile data
histopathological and histochemical 
evaluation of kidney
Tissue preparation: neutral-buffered formalin-fixed kidney 
tissues were trimmed at 2–3 mm thickness,   processed in 
graded isopropyl alcohol, cleared in xylene, and   infiltrated 
with paraffin. Paraffin-embedded 4-  micron-thick serial kid-
ney sections were taken and stained with either hematoxylin 
and eosin, periodic acid Schiff (PAS), or Masson’s trichrome 
staining.   Glomerulosclerosis was evaluated in a PAS-stained 
kidney section; nephropathy and tubule–interstitum changes 
were evaluated in   hematoxylin and eosin-stained and Mas-
son’s trichrome-stained kidney sections under light micros-
copy on a grade scale of 0 to 4 by a pathologist who was 
blinded to the treatment groups.
For glomerulosclerosis index (gSi)
In a PAS-stained kidney section, 100 glomeruli from each 
animal were evaluated on the scale of grade (G) 0 to 4 for 
glomerulosclerosis. G0 normal glomeruli without any 
change; G1 minimal glomerulosclerosis characterized by the 
focal expansion of mesangial matrix and thickening of base-
ment membrane; G2 mild glomerulosclerosis characterized 
by the global expansion of mesangial matrix and thicken-
ing of basement membrane with an increase in cellularity; 
G3 moderate glomerulosclerosis characterized by the global 
expansion of mesangial matrix and thickening of basement 
membrane with an increase in cellularity, infiltration of 
foam cells, and hypertrophied podocytes and epithelial cells; 
G4 severe glomerulosclerosis characterized by a more severe 
form of G3 glomerulosclerosis or completely sclerosed or 
obsolescence of glomeruli. An index of glomerulosclerosis 
for each animal has been derived by:
GSI = (G0 × 0) + (G1 × 1) + (G2 × 2) + (G3 × 3) + (G4 × 4)
Total number of glomeruli scored.
Where G0, G1, G2, G3, and G4 are the total no of glomeruli 
showing respective grade glomerulosclerosis.
Measurement of CV functional 
parameters
Measurement of cardiac function was performed terminally 
in the obese ZSF1 rats implanted with telemetry transmitter 
using Millar Pressure Volume (PV) System (Millar Instru-
ments, Houston, TX, USA).20 These data were generated 
to assess whether chronic treatment in the disease model 
influences cardiovascular function adversely. A microtip 
PV catheter (SPR-838) was inserted into the right carotid 
artery and advanced into the left ventricle (LV). A poly-
ethylene catheter was inserted into the left jugular for 
fluid administration. After stabilization for 10–20 minutes, 
LV-PV signals were recorded continuously at a sampling 
rate of 1000 per second using an MPVS-300 conductance 
system (Millar Instruments) coupled to a PowerLab 8/30 
(ADInstruments, NSW, Australia). 50 µl of 20% saline was 
injected intravenously so as to establish a parallel conduc-
tance volume from a shift of PV relations, and this was 
used for correction for the cardiac mass volume. LV-PV 
relations were also captured by transiently compressing 
the inferior vena cava.
LV parameters were computed using cardiac PV analysis 
software (PVAN3.2, Millar Instruments). Volume calibrations 
were performed with a   Millar volume calibration cuvette, 
which consists of a 1-cm-deep cylindrical block with cylindri-
cal holes of known diameters ranging from 2 mm to 11 mm 
filled with fresh heparinized whole rat blood. The linear 
volume–conductance   regression of the absolute volume in 
each cylinder versus the raw signal acquired by the conduc-
tance catheter was used for the volume calibration.
The results indicated that the cardiac functional param-
eters recorded showed no deterioration with TRC150094 
treatment in comparison with the control group. Instead, a 
trend towards better preserved cardiovascular function was 
observed in the TRC150094-treated group in comparison 
with the control group (Table E).
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Table A effect of Trc150094 on body weight gain and food intake in male obese ZSF1 rats
Parameter Treatment week Control 6 mg/kg 12 mg/kg
Body weight gain (g) 6 110.1 ± 6.21   94.9 ± 3.7*   97.1 ± 5.6***
16 177.9 ± 11.0 170.7 ± 5.8 155.2 ± 5.6*
24 207.1 ± 13.9 203.2 ± 6.6 199.6 ± 10.6
Food intake (g/day) 0   40.5 ± 3.1   42.7 ± 1.0   41.3 ± 1.6
6   39.6 ± 1.6   39.4 ± 0.9   38.4 ± 1.4
16   35.2 ± 2.2   35.7 ± 1.0   33.9 ± 2.0
24   30.6 ± 1.6   30.9 ± 1.2   31.7 ± 1.9
Notes: Values are mean ± SeM (standard error of mean). *P , 0.05; ***P , 0.1 vs control group.
Table C effect of Trc150094 on urinary microalbumin to creatinine ratio in male obese ZSF1 rats
Treatment Treatment week
0 6 16 24
control 16.9 ± 2.9 246.0 ± 19.4 356.7 ± 24.4 454.6 ± 45.1
Trc150094, 6 mg/kg 15.6 ± 2.2 210.5 ± 18.2 329.8 ± 23.3 460.2 ± 45.1
Trc150094, 12 mg/kg 11.4 ± 2.3 190.2 ± 11.6* 287.2 ± 23.01* 280.5 ± 49.4*
Notes: Values are mean ± SeM (standard error of mean). *P , 0.05 vs control group.
Table B effect of Trc150094 on plasma lipid parameters in male obese ZSF1 rats
Parameter Treatment week Male
Control 6 mg/kg 12 mg/kg
Fasting plasma Tg 0 2547 ± 213 2497 ± 193 2596 ± 142
6 3471 ± 419 3121 ± 306 3035 ± 168
16 6327 ± 750 4974 ± 778 5499 ± 555
24 8278 ± 1331 8056 ± 949 8147 ± 1590
Fasting plasma Tc 0 233.2 ± 8.8 220.8 ± 7.3 231.1 ± 8.2
6 349.2 ± 21.2 306.6 ± 18.8 289.5 ± 17.5*
16 632.1 ± 58.0 612.4 ± 78.9 585.4 ± 54.3
24 704.5 ± 91.0 820.8 ± 85.5 760.7 ± 106.5
neFA 0 0.85 ± 0.08 0.97 ± 0.10 0.98 ± 0.10
6 1.01 ± 0.05 0.86 ± 0.08 1.01 ± 0.12
16 0.91 ± 0.05 0.86 ± 0.04 0.75 ± 0.05*
24 3.71 ± 0.32 3.22 ± 0.45 3.27 ± 0.33
Notes: Values are mean ± SeM. *P , 0.05 vs control group.
Abbreviations: neFA, non-essential fatty acid; SeM, standard error of mean; Tc, total cholesterol; Tg, triglycerides.
Table D glomerulosclerosis index (gSi) and mean severity of nephropathy
GSI Nephropathy
Control TRC150094  
6 mg/kg
TRC150094  
12 mg/kg
Control TRC150094  
6 mg/kg
TRC150094   
12 mg/kg
2.01 ± 0.07 2.07 ± 0.08 1.83 ± 0.06 2.39 ± 0.29 2.33 ± 0.17 1.92 ± 0.23
Note: Values are mean ± SeM (standard error of mean).Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
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Table E effect of Trc150094 on cardiovascular functional parameters in male obese ZSF1 rats
Parameters Control TRC150094  
12 mg/kg
heart rate (beats/minute)   288.6 ± 12.0   288.0 ± 22.5
cardiac output (µL/minute) 15131.7 ± 774.7 16895.5 ± 2371.2
+dP/dt (mmhg/second)   7576.4 ± 1286.6   8432.5 ± 571.2
−dP/dt (mmhg/second)   7024.6 ± 971.1 8198.3 ± 1025.4
LV pressure decay, Tau (millisecond)     12.3 ± 0.7     12.1 ± 0.9
eSPVr slope (mmhg/µL)     1.3 ± 0.2     1.8 ± 0.4
eDPVr slope (mmhg/µL)     0.07 ± 0.01     0.06 ± 0.003
PrSW (mmhg)     66.9 ± 11.9   102.9 ± 25.9
Notes: Values are mean ± SeM (standard error of mean). n = 4–5.
Abbreviations: eDPVr, end diastolic pressure-volume relationship; eSPVr, end systolic pressure-volume relationship; LV, left ventricular; PrSW, pre-recruitable stroke 
work.